The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Stephen H. Gillespie

Royal Free and University College Medical School

University College London

London NW3 2PF

United Kingdom

[email]@rfc.ucl.ac.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Royal Free and University College Medical School, University College London, London NW3 2PF, United Kingdom. 2002 - 2005
  • Department of Medical Microbiology, Royal Free and University College London, UK. 2001 - 2004
  • University College London, Royal Free Campus, London NW3 2PF, UK. 2004
  • Royal Free & University College Medical School, London. 2001

References

  1. Novel PCR-restriction fragment length polymorphism method for determining serotypes or serogroups of Streptococcus pneumoniae isolates. Batt, S.L., Charalambous, B.M., McHugh, T.D., Martin, S., Gillespie, S.H. J. Clin. Microbiol. (2005) [Pubmed]
  2. Cutaneous Larva Migrans. Gillespie, S.H. Curr. Infect. Dis. Rep (2004) [Pubmed]
  3. New tricks from an old dog: streptococcal necrotising soft-tissue infections. Gillespie, S.H. Lancet (2004) [Pubmed]
  4. Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation. Gillespie, S.H., Voelker, L.L., Ambler, J.E., Traini, C., Dickens, A. Microb. Drug Resist. (2003) [Pubmed]
  5. A novel method for evaluating the antimicrobial activity of tuberculosis treatment regimens. Gillespie, S.H., Charalambous, B.M. Int. J. Tuberc. Lung Dis. (2003) [Pubmed]
  6. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Gillespie, S.H. Antimicrob. Agents Chemother. (2002) [Pubmed]
  7. Microbes sans frontières. Gillespie, S.H. Lancet (2002) [Pubmed]
  8. A reiterative method for calculating the early bactericidal activity of antituberculosis drugs. Gillespie, S.H., Gosling, R.D., Charalambous, B.M. Am. J. Respir. Crit. Care Med. (2002) [Pubmed]
  9. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Gillespie, S.H., Voelker, L.L., Dickens, A. Microb. Drug Resist. (2002) [Pubmed]
  10. Multiple drug-resistant Mycobacterium tuberculosis: evidence for changing fitness following passage through human hosts. Gillespie, S.H., Billington, O.J., Breathnach, A., McHugh, T.D. Microb. Drug Resist. (2002) [Pubmed]
  11. Toxocara: dogwalking and playing fields. Gillespie, S. Br. J. Sports. Med (2001) [Pubmed]
  12. A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model. Gillespie, S.H., Morrissey, I., Everett, D. J. Med. Microbiol. (2001) [Pubmed]
 
WikiGenes - Universities